| Literature DB >> 31540341 |
Pedro J Sánchez-Cordón, Alejandro Nunez, Aleksija Neimanis1, Emil Wikström-Lassa1, María Montoya2, Helen Crooke3, Dolores Gavier-Widén1,4.
Abstract
After the re-introduction of African swine fever virus (ASFV) genotype II isolates into Georgia in 2007, the disease spread from Eastern to Western Europe and then jumped first up to Mongolian borders and later into China in August 2018, spreading out of control and reaching different countries of Southeast Asia in 2019. From the initial incursion, along with domestic pigs, wild boar displayed a high susceptibility to ASFV and disease development. The disease established self-sustaining cycles within the wild boar population, a key fact that helped its spread and that pointed to the wild boar population as a substantial reservoir in Europe and probably also in Asia, which may hinder eradication and serve as the source for further geographic expansion. The present review gathers the most relevant information available regarding infection dynamics, disease pathogenesis and immune response that experimental infections with different ASFV isolates belonging to genotype I and II in wild boar and feral pigs have generated. Knowledge gaps in areas such as disease pathogenesis and immune response highlights the importance of focusing future studies on unravelling the early mechanisms of virus-cell interaction and innate and/or adaptive immune responses, knowledge that will contribute to the development of efficacious treatments/vaccines against ASFV.Entities:
Keywords: African swine fever virus; experimental infection.; genotype I and II; wild boar
Year: 2019 PMID: 31540341 PMCID: PMC6783972 DOI: 10.3390/v11090852
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Experimental infections of wild boar with African swine fever virus (ASFV) Genotype II isolates. Information about experimental conditions of domestic pigs that were infected in parallel with wild boar have also been provided. (GT): genotype; (WB): wild boar; (DP): domestic pigs; (HAU): haemagglutinating units; (TCID): Tissue Culture Infectious Dose (TCID), (ND): Not determined; (NA): Not administered (in contact animals).
| Isolate/ Origin | GT | Type /Number of Animals | Estimated Age | Dose | Route of Exposure | Onset of Clinical Signs After Infection | Survival After Infection (dpi) | Ref. |
|---|---|---|---|---|---|---|---|---|
| Armenia 2008 | II | WB ( | 9 weeks | 106 TCID | Oral | 3–4 dpi (6) | 5–7 dpi (6) | [ |
| II | DP ( | Weaner pigs | NA | In contact | 11–12 dpi (2)/ 20 dpi (1) | 17 dpi (2)/ 25 dpi (1) | ||
| Chechen Republic 2009 | II | WB ( | 9 months | 103 HAU | Intramusc. | 3 dpi (1) | 5 dpi (1) | [ |
| II | WB ( | 9 months | NA | In contact | 8 dpi (3) | 10 dpi (3) | ||
| Caucasus isolate | II | WB ( | 10 years | 3 × 106 TCID | Oral | ND | 8–9 dpi (4) | [ |
| Sow ( | 4–5 years | |||||||
| WB ( | Piglet | |||||||
| Armenia 2008 | II | WB ( | 4–5 months | 100 HAU (25 HAU after back titration) | Oronasal | WB: 2–5 dpi (1)/ 11–13 dpi (5) | WB: 11 dpi (1)/ 14–17 dpi (5) | [ |
| DP ( | 8–12 weeks | DP: 23 dpi (1)/ 30–33 dpi (5) | DP: 28 dpi (1)/ 34–36 dpi (5) | |||||
| II | WB ( | 4–5 months | 10 HAU (3 HAU after back titration) | Oronasal | WB: 0–9 dpi (2; runt animals)/ 14–19 dpi (4) | WB: 6–10 (2; runt animals)/ 18–23 dpi (4) | ||
| DP ( | 8–12 weeks | DP: 12–19 dpi (6) | DP: 17–23 dpi (6) | |||||
| North-Eastern Estonia | II | WB ( | 4 months | 104.5 HAU | Oronasal | 4–6 dpi (10) | 7–13 dpi (9)/ recovered WB (1) | [ |
| North-Eastern Estonia | II | 1 recovered WB and 3 WB (sentinels) | 5 months | NA | In contact | No clinical signs (4) | End of trial at 96 dpi. All animals (4) completely healthy. | [ |
| North-Eastern Estonia | II | Minipigs ( | 6 months | 105 HAU | Oronasal | Minipigs: 7 dpi (12) | Minipigs: 8–15 dpi (3)/recovered minipigs (9) | |
| DP ( | 6 months | DP: 4–6 dpi (4)/10 dpi (1). All animals without clinical signs from 19 dpi | DP: All animals recovered (5) | [ | ||||
| II | WB ( | 2 years (adults) | 106.5 HAU | Oronasal | Adults WB: 3–4 dpi (3) | Adult WB 8–9 dpi (3) | ||
| WB ( | 6 months (piglets) | Piglets WB: 3–4 dpi (2) | Piglets: 16–17 dpi (2) |
Experimental infections of wild boar and feral pigs with ASFV Genotype I isolates. (GT): genotype; (WB): wild boar; (DP): domestic pigs; (HAU): haemagglutinating units; (TCID): Tissue Culture Infectious Dose (TCID), (ND): Not determined; (NA): Not administered (in contact animals).
| Isolate/ Origin | GT | Type /Number of Animals | Estimated Age | Dose | Route of Exposure | Onset of Clinical Signs After Infection | Survival After Infection (dpi) | Ref. |
|---|---|---|---|---|---|---|---|---|
| Tor Sapienza | I | WB ( | Adults | ND (2–4 mL infected blood | Subcutaneous (base of the ear) | Temperature: from 24–72 h/clinical signs: from 5 dpi (2) | 11–13 dpi (2) | [ |
| Nemi | I | WB ( | Young | ND (2 mL of leukocyte culture infected) | Intramusc. (neck) | Temperature: from 24 h (1) | 11 dpi (1) | [ |
| WB ( | In contact | No clinical signs (1) | Euthanized weeks after infection | |||||
| I | WB ( | Young | ND (2 mL of leukocyte culture infected) | Oral | 6 dpi (1) | 20 dpi (1) | [ | |
| WB ( | In contact | 20 dpi (1) | 28 dpi (1) | |||||
| Sardinian 2008 | I | WB ( | ND | 106 HAU | Intramusc. | 3–4 dpi (4) | 5–8 dpi (4) | [ |
| E75 | I | CSFV PI WB ( | 7 weeks | 104 TCID | Intramusc. | CSFV PI WB: 4 dpi (3) | CSFV PI WB: 6–7 dpi (3) | [ |
| Pestivirus-free WB ( | Pestivirus-free WB: 4 dpi (3) | Pestivirus-free WB: 8–10 dpi (3) | ||||||
| Lisbon 1960 | I | Feral pigs (2) | Adults | 107 HAU | Intranasal | Feral pigs: 3–4 dpi (2) | Feral pigs: 7–8 dpi (2) | [ |
| I | Feral pigs (4) | Adults | NA | In contact | Feral pigs: 8–17 dpi (4) | Feral pigs: 14–20 dpi (4) | ||
| Dominic. Republic 1979 | I | Feral pigs (2) | Adults | 107 HAU | Intranasal | Feral pigs: 3–4 dpi (2) | Feral pigs: 11–16 dpi (2) | [ |
| I | Feral pigs (4) | Adults | NA | In contact | Feral pigs: 10–13 dpi (4) | Feral pigs: 19–22 dpi (4) |